Article Sidebar

Submitted
Aug 9, 2025
Accepted
Oct 8, 2025
Published
Dec 24, 2025
Download
pdf
Statistic
Read Counter : 0 Download : 0

Downloads

Download data is not yet available.

Main Article Content

Abstract

Background:


To analyze the factors influencing the mortality incidence of elderly patients with COVID-19 infection in Padang, West Sumatra, Indonesia.


Methods: This is a retrospective study at M. Djamil Hospital, Padang. Data was collected from the medical records of COVID-19 patients treated during July-September 2021.


Results: Of the 243 elderly patients who experienced COVID-19, the most deaths were male (58.6%) with an average age of 69.64 ± 7.74 years. Multivariate analysis showed that patients with critical-severe clinical symptoms (odds ratio (OR) 12.95; 95% confidence interval (CI) 6.66–25.19), heart disease (OR 6.94; 95% CI 1.63–29.60), respiratory rate ≥30 breaths per minute (OR 3.48; 95% CI 1.04–11.60), pulse ≥100 beats per minute (OR 2.88; 95% CI 1.03–8.04), using a ventilator or high-flow nasal cannula (OR 19.78; 95% CI 5.92–66.10), prothrombin time >13.16 second (OR 12.35; 95% CI 2.43–62.77), interleukin-6 >6 pg/mL (OR 15.19; 95%CI 2.53–91.26), and random blood glucose >199 mg/dL (OR 3.45; 95% CI 1.02–11.68) have a high risk of death.


Conclusion: Elderly patients with COVID-19 infection with critical-severe clinical symptoms accompanied by heart disease, using ventilator or high-flow nasal cannula, longer prothrombin time, high level of interleukin-6, and random blood glucose have higher risk of mortality.

Keywords

COVID-19 elderly mortality Public Health Health

Article Details

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

How to Cite
Mulyana, R., Elvira, D., & Martini, R. D. (2025). FACTORS ASSOCIATED WITH MORTALITY OF ELDERLY PATIENTS WITH COVID-19 INFECTION AT M. DJAMIL HOSPITAL, PADANG, WEST SUMATRA, INDONESIA : COVID-19 INFECTION. INDONESIAN JOURNAL OF HEALTH SCIENCES RESEARCH AND DEVELOPMENT (IJHSRD), 7(2), 122–132. https://doi.org/10.36566/ijhsrd/Vol7.Iss2/329

References

  1. 1. Akbar MI, Nurmaladewi N, Aspian P, Pagala I, Rustam M. Assessing the service quality at health service facilities during the COVID-19 pandemic in North Buton District, Indonesia. Public Health of Indonesia. 2022 Dec 13;8(4):116-22.
  2. 2. West Sumatra Province. Data pantauan COVID-19 Provinsi Sumatera Barat 2022 [2022 West Sumatra Province COVID-19 monitoring data]. 2022; https://corona.sumbarprov.go.id.
  3. 3. Dessie ZG, Zewotir T. Mortality-related risk factors of COVID-19: A systematic review and meta-analysis of 42 studies and 423,117 patients. BMC Infectious Diseases 2021; 21(1):855. https://doi.org/10.1186/s12879-021-06536-3.
  4. 4. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirus–infected pneumonia in Wuhan, China. JAMA 2020;323(11):1061-9. https://doi.org/10.1001/jama.2020.1585.
  5. 5. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. The Lancet Respiratory Medicine 2020;8(5):475-81. https://doi.org/10.1016/S2213-2600(20)30079-5.
  6. 6. Iftimie S, López-Azcona AF, Vicente-Miralles M, et al. Risk factors associated with mortality in hospitalized patients with SARS-CoV-2 infection: A prospective, longitudinal, unicenter study in Reus, Spain. PloS One 2020;15(9):e0234452. https://doi.org/10.1371/journal.pone.0234452.
  7. 7. Abul Y, Leeder C, Gravenstein S. Epidemiology and clinical presentation of COVID-19 in older adults. Infect Dis Clin N Am 2023;37:1–26.
  8. 8. Goldberg EM, Southerland LT, Meltzer AC, et al. Age-related differences in symptoms in older emergency department patients with COVID-19: Prevalence and outcomes in a multicenter cohort. J Am Geriatr Soc 2022;70(7):1918–30.
  9. 9. Cohen K, Ren S, Heath K, et al. Risk of persistent and new clinical sequelae among adults aged 65 years and older during the post-acute phase of SARS-CoV-2 infection: retrospective cohort study. BMJ 2022;376:e068414.
  10. 10. Katsoularis I, Fonseca-Rodrı´guez O, Farrington P, et al. Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: nationwide self-controlled cases series and matched cohort study. BMJ 2022;377:e069590.
  11. 11. Damayanthi HD, Prabani KI, Weerasekara I. Factors associated with mortality of older people with COVID-19: A systematic review and meta-analysis. Gerontology and Geriatric Medicine 2021;7. https://doi.org/10.1177/23337214211057392.
  12. 12. Shaw AC, Bandaranayake T. Immunology of aging. In Halter JB, Ouslander JG, Studenski S, et al, (Eds.). Hazzard’s geriatric medicine and gerontology 7th ed. New York: McGraw-Hill Education 2017, pp. 33-49.
  13. 13. Gu T, Chu Q, Yu Z, et al. History of coronary heart disease increased the mortality rate of patients with COVID-19: A nested case–control study. BMJ Open 2020;10(9), e038976. https://doi.org/10.1136/bmjopen-2020-038976.
  14. 14. Krishna BA, Metaxaki M, Sithole N, et al. Cardiovascular disease and COVID-19: a systematic review. IJC Heart & Vasculature 2024;54(101482). https://doi.org/10.1016/j.ijcha.2024.101482.
  15. 15. Harrison SL, Buckley BJ, Rivera-Caravaca JM, et al. Cardiovascular risk factors, cardiovascular disease, and COVID-19: an umbrella review of systematic review. European Heart Journal – Quality of Care and Clinical Outcomes 2021;7:330-9. https://doi:10.1093/ehjqcco/qcab029.
  16. 16. Gopalan N, Senthil S, Prabakar NL, et al. Predictors of mortality among hospitalized COVID-19 patients and risk score formulation for prioritizing tertiary care—an experience from South India. PloS One 2022; 17(2): e0263471. https://doi.org/10.1371/journal.pone.0263471.
  17. 17. Lee JY, Kim HA, Huh K, et al. Risk factors for mortality and respiratory support in elderly patients hospitalized with COVID-19 in Korea. J. Korean Med. Sci. 2020;35(23):e223. https://doi.org/10.3346/jkms.2020.35.e223.
  18. 18. AbuRuz S, Al-Azayzih A, ZainAlAbdin S, et al. Clinical characteristics and risk factors for mortality among COVID-19 hospitalized patients in UAE: Does ethnic origin have an impact? PloS One 2022;17(3): e0264547. https://doi.org/10.1371/journal.pone.0264547.
  19. 19. De Terwangne C, Sorgente A, Tortora R, et al. Mortality rate and predictors among patients with COVID-19 related acute respiratory failure requiring mechanical ventilation: a retrospective single centre study. J Crit Care Med (Targu Mures) 2021;7(1);21-7. https://doi: 10.2478/jccm-2020-0043.
  20. 20. Rao AV, Cohen HJ. Oncology and aging: general principles. In Halter JB, Ouslander JG, Studenski S, et al. (Eds.). Hazzard’s geriatric medicine and gerontology,7th ed. New York: McGraw-Hill Education 2017, pp. 1423-40.
  21. 21. Avila-Nava A, Cortes-Telles A, Torres-Erazo D, et al. Serum IL-6: A potential biomarker of mortality among SARS-CoV-2 infected patients in Mexico. Cytokine 2021;143: 155543. https://doi.org/10.1016/j.cyto.2021.155543.
  22. 22. Hafez W, Nasa P, Khairy A, et al. Interleukin-6 and the determinants of severe COVID-19: a retrospective cohort study. Medicine 2023;102(45):p e36037. https://DOI: 10.1097/MD.0000000000036037.
  23. 23. Liu X, Wang H, Shi S, et al. Association between IL-6 and severe disease and mortality in COVID-19 disease: A systematic review and meta-analysis. Postgraduate Medical Journal 2022; 98(1165):871-9. https://doi.org/10.1136/postgradmedj-2021-139939.
  24. 24. Akbari H, Tabrizi R, Lankarani KB, et al. The role of cytokine profile and lymphocyte subsets in the severity of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. Life Sci. 2020;258:118167. https://doi: 10.1016/j.lfs.2020.118167.
  25. 25. Cifaldi L, Prencipe G, Caiello I, et al. Inhibition of natural killer cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome. Arthritis & Rheumatology 2015; 67(11): 3037-46. https://doi.org/10.1002/art.39295.
  26. 26. Permana H, Huang I, Susandi E, et al. The association of admission random blood glucose concentration and body-mass index with mortality in COVID-19 patients. Eur. Rev. Med. Pharmacol. Sci. 2021;25(22): 7144-50. https://doi.org/10.26355/eurrev_202111_27268.
  27. 27. Mirabella S, Gomez-Paz S, Lam E, et al. Glucose dysregulation and its association wirh COVID-19 mortality and hospital length of stay. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2022;102439. https://DOI: 10.1016/j.dsx.2022.102439.
  28. 28. Gianchandani R, Esfandiari NH, Ang L, et al. Managing hyperglycemia in the COVID-19 inflammatory storm. Diabetes 2020; 69(10):2048-53. https://doi.org/10.2337/dbi20-0022.
  29. 29. Brufsky A. Hyperglycemia, hydroxychloroquine, and the COVID‐19 pandemic. J. Med. Virol. 2020; 92(7): 770-5. https://doi.org/10.1002/jmv.25887.
  30. 30. Kohio HP, Adamson AL. Glycolytic control of vacuolar-type ATPase activity: A mechanism to regulate influenza viral infection. Virology 2013;444(1-2):301-9. https://doi.org/10.1016/j.virol.2013.06.026.
  31. 31. Long H, Nie L, Xiang X, et al. D-Dimer and prothrombin time are the significant indicators of severe COVID-19 and poor prognosis. BioMed Res. Int. 2020;6159720. https://doi.org/10.1155/2020/6159720.